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ABSTRACTS - P~,tcr 33A 
both aofflc NE (medlan:318 tO 337 p~ml) and CS NE (median 368 to 542 
gg/ml') In all pta and doubled the tmnsoa~a© sptllovor ot NE (median -99 Io 
- 198 pg/ml "~ )whereas node, CS and transcar~nc NE were not stgnlfeantly 
modified during P (median ~llover 8B to - 128 pg/ml: NS) or DOF (median 
sl~llover 82 tO -69 pg/ml; NS) infusions, Thus, in contrast o DOF, IV AMIO 
• gnlflcaNly Increased Carcll~ I~q~tthatl¢ ddve whk:h could partially explain 
the smaller (:IT p~,.,~-,~al~on e~J the low inck~,~c¢,e of ~rsedes de p~n~s 
during IV AMIO admtntalxntion, Fudhet stud1(~ am ~ tO doKemlne 
~ ~ h ~  ¢0~ allo I !~  ~ ~ antlaffhy~ a¢~y O! IV 
amtedarone, "p ,~ 0,0~ v~ P; ~ p < 0.05 vS OOF 
~ F J . d y  Ef f lca~/and Complk:Mlon~ of  e f l~ l l ln l  
~mk~arone  for  Ah~l l  Flbdl lMlon in Adv~ncld  
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M.S, W~nf~cl, MH. Dralm~f, WG. S~nson,  L.W. S~evanson_ grn~/~m 
~d ~ Holm4 8o~ MA. USA 
Backgmun~ The ~ o~ m~a~ng a~damne tAM) am not weO, ciefN~ 
for PI~ with aM~ ~ (AFt) and ~ ~ Mill.ira (HF), 
~ Re¢on~ were m~wmd kx 37 ~,,7,,-,g,~ IRI ~ AM 
~ lot AFib ~ HF tree, e° admiumn, ~ al lasl feAow-up i
de~rm~l  for all plI. HF was due 1o CAD (16.43%) al¢0h01 (3B%), valve 
± t, LVIEF 24 ± ~,  LA du~ensm 5.3 ± 08 O~t, medum AF~ doralk:m 12 
mos. PtS mceNed oral AM stadmg at 1-2 ± 0.2 ~m/day. 
Re~sU/~- AM was decreased Io <1~0 ml~ m 9 ptm (24%), d~e m 
b r a ~  in S (14%), m~Mm~ HF m :2 (5%), 8rid Ot upset m 2 (5%). 
~ led fo permanent pacm~uikm  7 pts and i~N~l~ng d~gemn in 
anofh~ 8 pts. Comem~ ~o sinus d~l~n rammed ~,~,~-,ao,m'y in 3 i~s 
and with ~ caedlevetskm in 26 (anm. 7 ± 2 gins folal AM), fo~ 78% 
m_ ~,.ce~_ __ Altei median foaow-uD 9.5 mos, 21 (57%) of aft pts were 
slgl out ot AF~b. Aftra clischarge, 3pts had ~ anol'nee had 
hypomym~n and ~ ~vm ~ and t showad ~¢~y.  
Conctus~o~- AM wire eke'Ideal cardiovemon hes I~  indmi =rod modm- 
ate latin success foe AFib and advanced HF. The malor eady mm'oidily is 
bradycaeclk~ requmng pacemake¢ Gr d~sconlmuabon fcBgovin tn 41% 0t pts. 
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Bac~gm~m,3: The ~ AHCPR guiOelmes foe CHF dmease management 
do not recommend the routine use of throne anl¢oagulabon and c~e 1~e 
lack of ~ t~tals in II~s area. Howevsr. warfarin is osed mulme;y by 
many ~ wilh me geal of prevention of LV mraw~us fom~;mon and 
~ eml~at~n, we sel oui Io imestigate the risk ~ of Itmse 
patients with LV thmmbus idontified by echocan:liogrephy as pro1 ol a hearl 
transplantation evaluation. 
Me#~(/s. We ido~tified 28 cases with LV t h ~  in a 144 patient con- 
seeulhm sedes wilh Iongitudinel follew.up for a median of 25 monlha. Pabems 
with prosthetic valves or EF > 35% were exctuded. Using an unmatched case- 
controf design and muttivacate techniques. 35 clinical and echocardiogmphic 
variables were evalualed for their independent relationship to LV lhrombus 
tonv, ation and subsequent thmmboembolism. 
Resuh's: The mean age of cases (n = 28) and controls (n = 116) was 502 
± 11.0 vs. 54.2 ± 11,1 years, with 22 (78.6%) and 78 (67.2%) being male. p 
> 0.05. The mean EF was 17.5 ± 5.5 vs. 20.0 ± 6.9 respectively, p > 0.05. 
The groups were likewise similar with respect to baseline characteristics. 
medic.at=on use. and comorbidities. Multiple logistic regression revealed an 
ischemic etiology of the ca~diomyopathy. OR = 3.04. 95% CI 1.04-8.83. p = 
0.04 and LV chamber size (LVIDD mm unit increment above referent). OR = 
1.09. 95% CI 1.03-1.16. p = 0.004. to be independent predictors of LV throm- 
bus formation when controlling for w~,darin and ASA utilization. All thrombi 
appeared at LVIDD >60 mm with a consistent, graded relationship seen be- 
tween thrombi frequency and increasing chamber size. Peripheral embolism 
occurred in ,5 (17.9%) vs. 13 (11.2%) of cases and controls respectively, p = 
0.34. 
Conclusions: These data support a risk-adjusted approach for the deci- 
sion to use warfarin in CHF patients. Those patients with ischemic ardiom~ 
opathies and dilated LV chamber sizes (LVIDD >60 ram) appear to be at 
particulady high risk. Future randomized trials in this group are warranted. 
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Heart FMhlm - l l eoml ry  Endpoh~tl e~ the 
DIAMOND~HF Study 
L. Kaber, The Oar~h/m, eee/~t~m #,4~,~ a n d ~  ON 
(Dt~MOND) ~ ll~<,,n< , ~./~, ot Ca~Lg~,  ~,meee Ummq,~v 
BaotgtOWld: Th~ DIAMONI)-CHF Iludy ¢lemonltllltod ~ ~ w~ 
~afe m pm~m~ w~ congt~N~ t.mrt fa~w~ (CH~, O~ ot 8 mm.m~ 
M~hod~' In th~ 01AMOND t~ 1518 P411~m~ to hot~M w~ 
CHF alXI wflh IIt~'~'~ left ~INft~laf syltoItc d ~  (will mott0~  
1 ~:, ~ - ~ . g  to ~ fmclkm below ~%) m m~mte ld  to 
a~a, ve dok~lk~ (03S-1 mg ¢la~y) 0, ~ m a ~ ~ ~ 
I~nm~al fe~ow up vra= ~ mor~,  EigM tmco~aW ~ were: i,,Iolliil 
~t~sKxl  w,h CHF req~nng ~-,ma~ m ~ne~ MCHF, m4olypes M 
~¢ammt. ~kyva=¢uta~  in ~ w~ atmd mmv~mo~, mveca~'~t 
mta~'lm~ e~,h an~ damng ct~u'~t~ otdo f~t~ (~ 300 lmtmm~). 
R~m~: Them were 228 hO~l~al ~ w~h wonleemg of CHF on 
dof~;~iu and 2g0 en p~cebo. The nsk mdu¢Imn was 0.TS ~h 95% ~ 
dent° ~m~its 0.63k-O,89. p ,< 0.001, Thls nlk indic!ran was sun in pslienls 
ea~ wem neuUl. 
worllenmg ol CHF. Th~ ~ ~ fo be i ~  i n d ~  of 1tin 
effect of the drog on atrial Ittm]la~on. 
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Back~ Not only ~ t~t al~o immune ach-cat~on may nave an 
a~onant  rote m me pmgmmon ot cc<~ heart ~ture (OHF1. Chn~c 
effec~ ol angiolmmm It (ang II) type 1 receptor a n ~  on the mmcane 
system remains unknown. 
Mef/xx~¢ To ¢lalmm/ne 1he chronic effects ( 14 weeks) of ang II b/p° I 
anta0o,~st 0rCV-llS) on plasma k.mts of cy~kmes anO soluble 
a(~esmn ~ were e~aluated m n~ld to modera~ CHF palmnts In 
= 14, electron frachon (El:) <45%, NYHA class I1-t11] and compared w~l 
p~acebo (n = S) 
Resuns: 
NYH& class EF Ang II IL-6 TNF_  MC/EM- 1 sVCNdb 1
Pm-TCV 25  37 34 4 IS 54 324 865 
TCV 1 6" 41" S0" 25" 4.3" 2159" 669" 
(IL-6 = mtevletd~n 6. TNF= = tLZmO~ t~crosm faclor ~, sfCAM-I = soluble mMecellul~ 
a ~  ~ 1 .  sVCAM-1 = soh,4~e vasc-,Jlar aolles~n m0Mcuks-t "=p < 0.05 VS, 
pre-'rcv). 
Them ~ no ~ changes of ~ paramme~ and neurol~moral 
a~l ~ levis in ff~e placebo group. In ~ plasma levals of IL-6, 
TNF~e. stCAM-1, and sVCAM-1 were ~,~-d;'~-./deCtlrased co;i-.;;d~,~; with 
the increase m EF and wilh ~ m symptoms in the TCV group, 
Conc/tn~...~-  findings ~ IJlat the chrome treatment of ang 11 
I recapfor antegonisl mtprove the actwations of the m~Jne system in 
patients wtfll CHE 
